Antares Pharma to Present at Bio InvestorForum 2005

Antares Pharma, Inc.
(AMEX: AIS), announced today that it will be presenting to investors and other
interested parties at the upcoming Bio InvestorForum on October 19, 2005 at
2:20 p.m. Eastern Time. The Forum will be held at the Palace Hotel, San
Francisco, CA. The Bio InvestorForum profiles the top life science growth
companies in 2005 as well as those poised to join the growth "watch list" in
2006. The Forum will include more than 190 public and venture-stage
companies.

About Antares Pharma
Antares Pharma is a specialized pharma product development company with
patented drug delivery systems and injectable device engineering capabilities.

The Company's current technology platforms include its ATD(TM) (Advanced
Transdermal Delivery) system, Easy Tec(TM) oral fast-melt technology, and
subcutaneous injection technology platforms (Vibex(TM) disposable mini-needle
injection device and Valeo(TM) and Vision(R) reusable needle-free injection
devices). Antares Pharma is committed to leveraging its multiple drug
delivery platforms to add value to existing drugs and to create new products
and devices. The Company believes its product pipeline addresses unmet
medical needs by reducing side effect profiles, improving safety, increasing
effectiveness, and improving patient compliance and convenience.
The Company has active programs with several pharmaceutical and
distribution companies for a number of indications and applications, including
diabetes, growth disorders, obesity, female sexual dysfunction and other
hormone therapy. Its needle-free injector system is distributed in more than
30 countries for the administration of insulin and is marketed for use with
human growth hormone through licensees in most major regions of the world.
Licensees also market an ibuprofen gel in several major European countries.
In addition, Antares Pharma is undertaking development or is conducting
research on several product opportunities that it expects will form the basis
of its specialized pharma program.
Antares Pharma has corporate headquarters in Exton, Pennsylvania, with
subsidiaries performing research, development, manufacturing and product
commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in
nature are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties,
which could cause actual results to differ materially and which are identified
from time to time in the Company's reports filed with the U.S. Securities and
Exchange Commission. Antares Pharma claims the protection of the Safe Harbor
for forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995.

For more information, visit Antares Pharma's web site at
http://www.antarespharma.com and its needle-free product website,
http://www.mediject.com. Information included on the Company's websites is
not incorporated herein by reference or otherwise.